Protein C zymogen in adults with severe sepsis or septic shock.
Med Intensiva
; 38(5): 278-82, 2014.
Article
en En
| MEDLINE
| ID: mdl-23876943
ABSTRACT
INTRODUCTION:
Activated protein C is associated with a risk of bleeding and its effects on survival in septic shock patients are questionable. Protein C zymogen has no risk of bleeding and improves the outcome of patients with septic shock. We hereby describe the largest published case series of adult patients receiving protein C zymogen. DESIGN, SETTING ANDPARTICIPANTS:
A prospective study on 23 adult patients with severe sepsis or septic shock, two or more organ failures and at high risk for bleeding, treated with protein C zymogen (50IU/kg bolus followed by continuous infusion of 3IU/kg/h for 72h).RESULTS:
The Z-test evidenced a significant reduction between the expected mortality (53%) and the observed mortality 30% (Z value=1.99, p=0.046) in our sample population. Protein C levels increased from 34±18% to 66±22% at 6h after PC bolus (p<0.001), and kept on increasing during 72h of administration (p<0.001 to baseline). Sequential Organ Failure Assessment (SOFA), score of organ dysfunction, decreased from baseline to 7 days after administration of protein C from 14±2 to 7±4 (p<0.001). No adverse event drug related was noted.CONCLUSION:
Protein C zymogen administration is safe and its use in septic patients should be investigated through a randomized controlled trial.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Choque Séptico
/
Proteína C
/
Sepsis
/
Precursores Enzimáticos
Tipo de estudio:
Clinical_trials
/
Evaluation_studies
/
Observational_studies
Idioma:
En
Revista:
Med Intensiva
Año:
2014
Tipo del documento:
Article